Ratings VYNE Therapeutics Inc.

Equities

VYNE

US92941V3087

Market Closed - Nasdaq 04:00:00 2023-11-27 pm EST Intraday chart for VYNE Therapeutics Inc. 5-day change 1st Jan Change
3.970 USD -1.00% +0.51% +47.04%

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.

Strengths

  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • For the past twelve months, EPS forecast has been revised upwards.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Analyst opinion has improved significantly over the past four months.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • The company has insufficient levels of profitability.
  • Over the past four months, analysts' average price target has been revised downwards significantly.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector : Pharmaceuticals

1st Jan change Capi. (M$) Investor Rating ESG Refinitiv
+47.04% 55 M $
C-
+61.69% 532 B $
C+
+47.80% 464 B $
B
-14.36% 364 B $
C+
-13.93% 246 B $
C+
-19.35% 216 B $
A+
+2.60% 201 B $
B-
-11.70% 195 B $
B+
-41.18% 170 B $
C+
+0.62% 141 B $
C+
Investor Rating
Trading Rating
-
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
-
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
-40% off Black Friday : Our subscriptions help you unlock the best investment opportunities.
Enjoy this offer